Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene

Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751

The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting

Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309

Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity

Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081

Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,030

IL-23 promotes tumour incidence and growth

Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820

A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates

Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076

mRNA vaccine for cancer immunotherapy

Miao, L., Zhang, Y., & Huang, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01335-5 · Cited by 966

Enhancing cancer immunotherapy with nanomedicine

Irvine, D. J., & Dane, E. L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 908

Interleukins in cancer: from biology to therapy

Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00363-z · Cited by 822

Nanodelivery of nucleic acids

Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719

Recent advances in mRNA vaccine technology

Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512

The landscape of mRNA nanomedicine

Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511

Intratumoural administration and tumour tissue targeting of cancer immunotherapies

Melero, I., Álvarez, E. C., Álvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 505

mRNA-based cancer therapeutics

Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 506

mRNA therapeutics in cancer immunotherapy

Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376

Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects

Kon, E., Ad‐El, N., Hazan‐Halevy, I., Stotsky‐Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 393

Impact of lipid nanoparticle size on mRNA vaccine immunogenicity

Hassett, K. J., Higgins, J. S., Woods, A., Levy, B., Xia, Y., Hsiao, C. J., Acosta, E. P., Almarsson, Ö., Moore, M. J., & Brito, L. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.021 · Cited by 382

Impact of mRNA chemistry and manufacturing process on innate immune activation

Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354

Three decades of messenger RNA vaccine development

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342

Nucleic acid delivery for therapeutic applications

Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 351

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging

Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282

Emerging mRNA technologies: delivery strategies and biomedical applications

Xiao, Y., Tang, Z., Huang, X., Chen, W., Zhou, J., Liu, H., Liu, C., Kong, N., & Tao, W. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00617g · Cited by 255

Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity

Li, Y., Su, Z., Zhao, W., Zhang, X., Momin, N., Zhang, C., Wittrup, K. D., Dong, Y., Irvine, D. J., & Weiss, R. (2020) · Nature Cancer · doi:10.1038/s43018-020-0095-6 · Cited by 233

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

Hewitt, S. L., Bailey, D., Zielinski, J. F., Apte, A., Musenge, F. M., Karp, R., Burke, S., Garçon, F., Mishra, A., Gurumurthy, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0472 · Cited by 231

Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models

Hotz, C., Wagenaar, T. R., Gieseke, F., Bangari, D. S., Callahan, M., Cao, H., Diekmann, J., Diken, M., Grunwitz, C. R., Hebert, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc7804 · Cited by 223

Engineering cytokine therapeutics

Deckers, J., Anbergen, T., Hokke, A. M., de Dreu, A., Schrijver, D. P., de Bruin, K., Toner, Y. C., Beldman, T. J., Spangler, J. B., de Greef, T. F. A., et al. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00030-y · Cited by 234

Enhancing in situ cancer vaccines using delivery technologies

Gong, N., Alameh, M., El-Mayta, R. D., Xue, L., Weissman, D., & Mitchell, M. J. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00974-9 · Cited by 197

Targeted modulation of immune cells and tissues using engineered biomaterials

Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 170

mRNA cancer vaccines: Advances, trends and challenges

He, Q., Gao, H., Tan, D., Zhang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.011 · Cited by 171

An Overview of Nanoparticle Protein Corona Literature

Hajipour, M. J., Safavi‐Sohi, R., Sharifi, S., Mahmoud, N. N., Ashkarran, A. A., Voke, E., Serpooshan, V., Ramezankhani, M., Milani, A. S., Landry, M. P., et al. (2023) · Small · doi:10.1002/smll.202301838 · Cited by 162

Enhancing immunotherapy with tumour-responsive nanomaterials

Linderman, S. W., DeRidder, L. B., Sanjurjo, L., Foote, M. B., Alonso, M. J., Kirtane, A. R., Langer, R., & Traverso, G. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01000-6 · Cited by 165

mRNA vaccine in cancer therapy: Current advance and future outlook

Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 158

mRNA Delivery of a Bispecific Single‐Domain Antibody to Polarize Tumor‐Associated Macrophages and Synergize Immunotherapy against Liver Malignancies

Wang, Y., Tiruthani, K., Li, S., Hu, M., Zhong, G., Tang, Y., Roy, S., Zhang, L., Tan, J. H., Liao, C., et al. (2021) · Advanced Materials · doi:10.1002/adma.202007603 · Cited by 145

Intratumoral Immunotherapy: From Trial Design to Clinical Practice

Champiat, S., Tselikas, L., Farhane, S., Raoult, T., Texier, M., Lanoy, É., Massard, C., Robert, C., Ammari, S., de Baère, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0473 · Cited by 141

Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery

Hu, M., Li, X., You, Z., Cai, R., & Chen, C. (2023) · Advanced Materials · doi:10.1002/adma.202303266 · Cited by 142

Click activated protodrugs against cancer increase the therapeutic potential of chemotherapy through local capture and activation

Wu, K., Yee, N. A., Srinivasan, S., Mahmoodi, A., Zakharian, M., Oneto, J. M. M., & Royzen, M. (2021) · Chemical Science · doi:10.1039/d0sc06099b · Cited by 131

Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures

Eroshenko, N., Gill, T., Keaveney, M. K., Church, G. M., Trevejo, J., & Rajaniemi, H. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0577-1 · Cited by 122

mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy

Deng, Z., Tian, Y., Song, J., An, G., & Yang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.887125 · Cited by 130

Advancement of cancer immunotherapy using nanoparticles-based nanomedicine

Gowd, V., Ahmad, A., Tarique, M., Suhail, M., Zughaibi, T. A., Tabrez, S. S. M., & Khan, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.026 · Cited by 115

Tumor-Targeted Nanomedicine for Immunotherapy

Cabral, H., Kinoh, H., & Kataoka, K. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00518 · Cited by 115

Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress

Pires, I. S., Hammond, P. T., & Irvine, D. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100035 · Cited by 116

mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond

Sentí, M. E., del Valle, L. G., & Schiffelers, R. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115190 · Cited by 124

Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy

Zhang, Y., Hou, X., Du, S., Xue, Y., Yan, J., Kang, D. D., Zhong, Y., Wang, C., Deng, B., McComb, D. W., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01453-9 · Cited by 113

Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

Kang, J. H., Bluestone, J. A., & Young, A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.006 · Cited by 107

Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics

Mukai, H., Ogawa, K., Kato, N., & Kawakami, S. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2022.100450 · Cited by 108

mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients

Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111

From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer

Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 102

Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity

Hamouda, A. E. I., Filtjens, J., Brabants, E., Kancheva, D., Debraekeleer, A., Brughmans, J., Jacobs, L., Bardet, P. M. R., Knetemann, E., Lefesvre, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54877-9 · Cited by 102

RNA-based therapies: A cog in the wheel of lung cancer defense

Κhan, P., Siddiqui, J. A., Lakshmanan, I., Ganti, A. K., Salgia, R., Jain, M., Batra, S. K., & Nasser, M. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01338-2 · Cited by 104

The Pivotal Role of Chemical Modifications in mRNA Therapeutics

Liu, A., & Wang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.901510 · Cited by 102

Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation

Chen, H., Liu, D., Aditham, A. J., Guo, J., Huang, J., Kostas, F., Maher, K., Friedrich, M., Xavier, R. J., Zhang, F., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02393-y · Cited by 102

Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy

Yang, J., Zhu, J., Sun, J., Chen, Y., Du, Y., Tan, Y., Wu, L., Zhai, M., Wei, L., Li, N., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.010 · Cited by 99

Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy

Han, J., Lim, J., Wang, C. J., Han, J., Shin, H. E., Kim, S.-N., Jeong, D., Lee, S. H., Chun, B.-H., Park, C. G., et al. (2023) · Nano Convergence · doi:10.1186/s40580-023-00385-3 · Cited by 100

Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways

Wang, Y., Li, S., Hu, M., Yang, Y., McCabe, E., Zhang, L., Withrow, A. M., Ting, J. P. ‐., & Liu, R. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01624-2 · Cited by 99

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy

Zhao, Y., Liu, Z., Li, L., Wu, J., Zhang, H., Zhang, H., Lei, T., & Xu, B. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.707290 · Cited by 96

A New Era for Rare Genetic Diseases: Messenger RNA Therapy

Martini, P. G. V., & Guey, L. T. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.090 · Cited by 88

New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers

Chyuan, I., & Lai, J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113928 · Cited by 89

RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics

Pandey, P. R., Young, K. H., Kumar, D., & Jain, N. K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01528-6 · Cited by 89

Trained immunity: Target for prophylaxis and therapy

Ziogas, A., Bruno, M., van der Meel, R., Mulder, W. J. M., & Netea, M. G. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.10.015 · Cited by 90

Lipid-based nanosystems: the next generation of cancer immune therapy

Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 95

Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery

Mollé, L. M., Smyth, C. H., Yuen, D., & Johnston, A. P. R. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1809 · Cited by 95

Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States

Lim, S., Khoo, R., Juang, Y.-C., Gopal, P., Zhang, H., Yeo, C., Peh, K. M., Teo, J., Ng, S., Henry, B., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01337 · Cited by 80

mRNA in cancer immunotherapy: beyond a source of antigen

Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85

Tunable metal–organic frameworks assist in catalyzing DNAzymes with amplification platforms for biomedical applications

Zhu, X., Xu, J., Ling, G., & Zhang, P. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00386h · Cited by 79

Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4 mouse model of PFIC3

Wei, G., Cao, J., Huang, P., An, P., Skelton-Badlani, D., Vaid, K. A., Zhao, S., Wang, D. Q. ‐., Zhuo, J., Yin, L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.12.010 · Cited by 74

tRNA therapeutics for genetic diseases

Coller, J., & Ignatova, Z. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00829-9 · Cited by 72

Advances in engineering local drug delivery systems for cancer immunotherapy

Abdou, P., Wang, Z., Chen, Q., Chan, A., Zhou, D. R., Gunadhi, V., & Gu, Z. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1632 · Cited by 72

mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency

Cao, J., An, D., Galduroz, M., Zhuo, J., Liang, S., Eybye, M., Frassetto, A., Kuroda, E., Funahashi, A., Santana, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.017 · Cited by 70

Delivery routes matter: Safety and efficacy of intratumoral immunotherapy

Lombaerde, E. D., Wever, O. D., & Geest, B. G. D. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188526 · Cited by 69

Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer

Matos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez‐Barriocanal, Á., Arango, D., Conde, J. P., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.017 · Cited by 71

An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ

Ye, K., Li, F., Wang, R., Cen, T., Liu, S., Zhao, Z., Li, R., Xu, L., Zhang, G.-M., Xu, Z.-Y., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.010 · Cited by 66

IL-36 in chronic inflammation and cancer

Neurath, M. F. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.006 · Cited by 65

Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy

Yoo, Y. J., Lee, C. H., Park, S. H., & Lim, Y. T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.047 · Cited by 62

mRNA-Based Therapeutics in Cancer Treatment

Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65

Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein

de Picciotto, S., DeVita, N., Hsiao, C. J., Honan, C., Tse, S., Nguyen, M., Ferrari, J. D., Zheng, W., Wipke, B. T., & Huang, E. (2022) · Nature Communications · doi:10.1038/s41467-022-31130-9 · Cited by 60

Strategies targeting tumor immune and stromal microenvironment and their clinical relevance

Hu, M., & Huang, L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114137 · Cited by 60

The IL-1 family in tumorigenesis and antitumor immunity

Sun, R., Gao, D. S., Shoush, J., & Lu, B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.002 · Cited by 58

Lipid-Nucleic Acid Complexes: Physicochemical Aspects and Prospects for Cancer Treatment

Gaspar, R., Coelho, F., & Silva, B. F. B. (2020) · Molecules · doi:10.3390/molecules25215006 · Cited by 59

IL-36 cytokines in inflammatory and malignant diseases: not the new kid on the block anymore

Byrne, J., Baker, K. J., Houston, A. M., & Brint, E. K. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03909-4 · Cited by 57

Clinical progress of nanomedicine-based RNA therapies

Lim, S. A., Cox, A., Tung, M., & Chung, E. J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.018 · Cited by 57

Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors

Neshat, S. Y., Chan, C. H. R., Harris, J. J., Zmily, O. M., Est-Witte, S. E., Karlsson, J. E., Shannon, S. R., Jain, M., Doloff, J. C., Green, J. J., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122185 · Cited by 56

Nano-bio interactions in mRNA nanomedicine: Challenges and opportunities for targeted mRNA delivery

Saiding, Q., Zhang, Z., Chen, S., Xiao, F., Chen, Y., Li, Y., Zhen, X., Khan, M. M., Chen, W., Koo, S., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115116 · Cited by 59

mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo

Cao, Q., Fang, H., & Tian, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122628 · Cited by 56

Targeting strategies for mRNA delivery

Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 55

Novel Endogenous Engineering Platform for Robust Loading and Delivery of Functional mRNA by Extracellular Vesicles

Zickler, A. M., Liang, X., Gupta, D., Mamand, D. R., Luca, M. D., Corso, G., Errichelli, L., Hean, J., Sen, T., Elsharkasy, O. M., et al. (2024) · Advanced Science · doi:10.1002/advs.202407619 · Cited by 55

In situ genetic engineering of tumors for long-lasting and systemic immunotherapy

Tzeng, S. Y., Patel, K. K., Wilson, D. R., Meyer, R. A., Rhodes, K. R., & Green, J. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916039117 · Cited by 54

Lipid nanoparticles for RNA delivery: Self-assembling vs driven-assembling strategies

Nele, V., Campani, V., Moosavian, S. A., & Rosa, G. D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115291 · Cited by 58

Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines

Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 51

Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition

Yuan, J. D., Khilnani, A. D., Brody, J., Andtbacka, R. H. I., Hu‐Lieskovan, S., Luke, J. J., Diab, A. K., Marabelle, A., Snyder, A., Cao, Z. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.004 · Cited by 50

Enhanced Local Delivery of Engineered IL-2 mRNA by Porous Silica Nanoparticles to Promote Effective Antitumor Immunity

Shin, H., Kang, S., Won, C., & Min, D. (2023) · ACS Nano · doi:10.1021/acsnano.3c06733 · Cited by 49

mRNA vaccines in the context of cancer treatment: from concept to application

Fu, Q., Zhao, X., Hu, J., Jiao, Y., Yan, Y., Pan, X., Wang, X., & Jiao, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06033-6 · Cited by 59

Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery

Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53

Biomaterials-Mediated Engineering of the Immune System

Backlund, C. M., Jalili‐Firoozinezhad, S., Kim, B., & Irvine, D. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-040259 · Cited by 52

Nanoparticle-Mediated In Situ Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy

Walters, A. A., Santacana-Font, G., Li, J., Routabi, N., Qin, Y., Claes, N., Bals, S., Wang, J. T.-W., & Al‐Jamal, K. T. (2021) · ACS Nano · doi:10.1021/acsnano.1c04456 · Cited by 46

mRNA delivery in cancer immunotherapy

Zhong, Y., Du, S., & Dong, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.001 · Cited by 49

An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma

Deng, Z., Yang, H., Tian, Y., Liu, Z., Sun, F., & Yang, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975408 · Cited by 46

Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

Álvarez, M., Molina, C., de Andrea, C. E., Fernández-Sendin, M., Villalba-Esparza, M., González-Gomariz, J., Ochoa, M. C., Teijeira, Á., Glez‐Vaz, J., Aranda, F., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002953 · Cited by 44

Engineered mRNA Delivery Systems for Biomedical Applications

Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 46

Therapeutic synthetic and natural materials for immunoengineering

Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 44

Gene delivery for immunoengineering

Neshat, S. Y., Tzeng, S. Y., & Green, J. J. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.05.008 · Cited by 44

Overcoming delivery barriers in immunotherapy for glioblastoma

Rui, Y., & Green, J. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01008-2 · Cited by 44

Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer

Gregory, G. L., & Copple, I. M. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.12.016 · Cited by 43

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future

Perenkov, A. D., Sergeeva, A. D., Vedunova, M. V., & Krysko, D. V. (2023) · Vaccines · doi:10.3390/vaccines11101600 · Cited by 40

Abstract 1607: Durable efficacy and anti-cancer immunity following intratumoral administration of messenger RNAs encoding IL-36γ, IL-23 and OX40L

Frederick, J. P., Bai, A., Hewitt, S. L., Karp, R., Zielinski, J. F., Ichikawa, K., Apte, A., Bailey, D., Arnold, K., Farlow, S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-1607 · Cited by 1

Abstract 1711: Induction of anti-tumor immunity by intratumoral delivery of mRNA encoding cytokines and TNFRSF agonists

Gavigan, J.-A., Shi, C., Lampa, M., Malkova, N. V., Yu, Q., Qu, H., Levit, M. N., Wagenaar, T. R., Hotz, C., & Li, X. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1711 · Cited by 2

Immune checkpoint blockade combined with IL ‐6 and TGF ‐β inhibition improves the therapeutic outcome of m RNA ‐based immunotherapy

Bialkowski, L., der Jeught, K. V., Bevers, S., Joe, P. T., Renmans, D., Heirman, C., Aerts, J. L., & Thielemans, K. (2018) · International Journal of Cancer · doi:10.1002/ijc.31331 · Cited by 38

Abstract CT210: A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral injection alone and in combination with immune checkpoint blockade

Bauer, T. M., Patel, M. R., Jimeno, A., Wang, D., McDermott, J. D., Zacharek, S. J., Randolph, W., Johansen, L. M., Hopson, K., Frederick, J. P., et al. (2019) · Clinical Trials · doi:10.1158/1538-7445.sabcs18-ct210

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

Lint, S. V., Renmans, D., Broos, K., Goethals, L., Maenhout, S. K., Benteyn, D., Goyvaerts, C., Four, S. D., der Jeught, K. V., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 130